Skip to main content
Clinical Trials/CTRI/2023/11/059697
CTRI/2023/11/059697
Not yet recruiting
未知

A Multi-centric, Cross-sectional, Observational, Validation study of Pregnancy Test Kit for Rapid Detection of Pregnancy ? - NI

Mankind Pharma Limited0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Mankind Pharma Limited
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Healthy female subjects of child\-bearing age group of \=18 to \=50 years.
  • 2\. Who either request a pregnancy test, or require a pregnancy test for diagnostic studies or treatment?
  • 3\. Written informed consent from the subject, legally acceptable representative or parent and able to follow study procedures.

Exclusion Criteria

  • 1\. Subjects who are not able to or not willing to sign an IRB/IEC approved consent form.
  • 2\. Known pregnancy.
  • 3\. Symptomatic COVID\-19 suspected subjects (as per PI discretion).
  • 4\. Hemodynamically unstable.
  • 5\. Moderately to severely ill\-appearing or in moderate to severe pain.
  • 6\. Taken a hormonal preparation containing hCG in the last month, e.g., Pregnyl®
  • 7\. Recently miscarried subject with in 2 months before study participation.
  • 8\. Subject recently consumed birth control pills, Antipsychotics such as perphenazine, prochlorperazine, chlorpromazine, trifluoperazine, thioridazine and thiothixene, anti\-seizure/anticonvulsant drug carbamazepine, Anti\-nausea drugs, including prochlorperazine, perphenazine, chlorpromazine and promethazine etc. which can cause false positive result. .
  • 9\. Technically not possible to obtain blood from the study subject.

Outcomes

Primary Outcomes

Not specified

Similar Trials